Stability or improvement in forced vital capacity with nintedanib in patients with IPF

Kevin R Flaherty,[1] Martin Kolb,[2] Carlo Vancheri,[3] Wenbo Tang,[4] Craig S Conoscenti,[4] Luca Richeldi[5]

[1]University of Michigan Health System, Ann Arbor, Michigan, USA; [2]McMaster University, Hamilton, Ontario, Canada; [3]Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; [4]Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA; [5]Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli, Rome, Italy.

Supplementary material

Figure S1. Proportions of patients with degrees of decline and improvement in FVC in the INPULSIS® trials based on annual rate of change (mL/year)

Nintedanib



Placebo



Figure S2. Baseline FVC (mL) in subgroups by annual rate of change in FVC in the INPULSIS® trials



Figure S3. Baseline FVC (% predicted) in subgroups by annual rate of change in FVC in the INPULSIS® trials



Figure S4. Baseline DLco % predicted in subgroups by annual rate of change in FVC in the INPULSIS® trials



Figure S5. Proportion of patients with honeycombing on HRCT at baseline in subgroups by annual rate of change in FVC in the INPULSIS® trials



Figure S6. Change from baseline in FVC (mL) at week 52 in the INPULSIS® trials



Figure S7. Change from baseline in FVC % predicted at week 52 in the INPULSIS® trials